CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Gamida Cell Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Gamida Cell Ltd
PO Box 34670
Phone: +972 26595666p:+972 26595666 JERUSALEM, 91340  Israel Ticker: GMDAQGMDAQ
Filed for Insolvency on 3/26/2024
On 3/26/2024, Gamida Cell Ltd implemented Israeli debt arrangement proceedings by the Company Parties under Part X to the Israeli Insolvency and Financial Rehabilitation Law, 2018, in the District Court of Beer Sheba
On 4/22/2024, Gamida Cell Ltd filed a Chapter 15 Bankruptcy Petition #24-10847 in the U.S. Bankruptcy Court for the District of Delaware in order to gain recognition of its Israeli debt arrangement proceedings by the Company Parties under Part X to the Israeli Insolvency and Financial Rehabilitation Law, 2018, in the District Court of Beer Sheba dated 3/26/2024
Business Summary
Gamida Cell Ltd is an Israel-based clinical-stage biopharmaceutical company. The Company develops cell therapies that are designed to cure cancer and rare, serious hematologic diseases. The Company is leveraging its nicotinamide (NAM)-based cell expansion technology toto expand multiple cell types including stem cells and natural killer (NK) cells while maintaining their original phenotype and potency. The following are the Company's clinical pipeline products: Omidubicel dedicated to hematologic malignancies and severe aplastic anemia; GDA-201 dedicated for treatment of non-Hodgkin Lymphoma; GDA-301, GDA-401, GDA-501 dedicated to treatment of solid tumors, GDA-601 dedicated to multiple myeloma.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202312/31/2023YesYes---

Industries
SIC Code Description
8733 Noncommercial research organizations
8731 Commercial physical and biological research
2836 Biological products, except diagnostic substances

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Non-Executive Chairwoman of the Board Shawn C.Tomasello 64 3/20/2023 6/1/2019
President, Chief Executive Officer, Director Abigail L.Jenkins 9/19/2022 9/19/2022
Chief Financial Officer TerryCoelho 62 5/22/2023 5/22/2023
9 additional Officers and Directors records available in full report.

Business Names
Business Name
GMDA
GMDAQ

General Information
Number of Employees: 145 (As of 12/31/2023)
Outstanding Shares: 154,050,953 (As of 3/22/2024)
Shareholders: 201
Stock Exchange: OTC
Federal Tax Id: 512601204
Fax Number: +972 26595616


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, April 26, 2024